Baseline characteristics
| Biologic naïve (n=674) | Biologic failure (n=1676) | |
| Age, years | 59.9 (12.7) | 57.0 (12.5); n=1675 |
| Female, n (%) | 496 (73.6) | 1379 (82.3) |
| BMI, kg/m2 | 27 (5.4); n=645 | 27.1 (5.6); n=1595 |
| BMI, n (%) | ||
| <25 kg/m² | 266 (41.2) | 648 (40.6) |
| 25–<30 kg/m² | 224 (34.7) | 542 (34.0) |
| ≥30–<35 kg/m² | 104 (16.1) | 266 (16.7) |
| ≥35 kg/m² | 51 (7.9) | 139 (8.7) |
| RA duration, years | 7.2 (8.2); n=669 | 12.1 (9.2); n=1669 |
| Number of previous biologics, n (%) | ||
| 1 | NA | 728 (43.4) |
| 2 | 589 (35.1) | |
| >2 | 359 (21.5) | |
| Previous csDMARDs, n (%) | ||
| MTX | 621 (92.1) | 1550 (92.5) |
| Leflunomide | 279 (41.4) | 951 (56.7) |
| Hydroxychloroquine/chloroquine | 229 (34.0) | 680 (40.6) |
| Sulfasalazine | 148 (22.0) | 577 (34.4) |
| TJC28 | 9.0 (6.5); n=634 | 10.4 (7.2); n=1598 |
| SJC28 | 6.6 (5.0); n=642 | 7.0 (5.6); n=1606 |
| DAS28 (ESR)* | 5.3 (1.2); n=582 | 5.5 (1.3); n=1422 |
| DAS28 (CRP)* | 4.8 (1.1); n=568 | 5.0 (1.1); n=1412 |
| CDAI* | 27.5 (11.5); n=565 | 30.0 (12.9); n=1388 |
| SDAI* | 29.1 (12.0); n=526 | 31.8 (13.6); n=1280 |
| PtGA (100 mm VAS) | 61.9 (20.3); n=621 | 65.4 (19.9); n=1538 |
| RF and anti-CCP antibody status, n/N (%) | ||
| Double negativity | 127/514 (24.7) | 267/1166 (22.9) |
| Single positivity | 77/514 (15.0) | 183/1166 (15.7) |
| Double positivity | 310/514 (60.3) | 716/1166 (61.4) |
| Radiographic erosion, n/N (%) | 353/608 (58.1) | 1034/1445 (71.6) |
| Radiographic erosion plus RF and anti-CCP double positivity, n/N (%) | 184/490 (37.6) | 512/1085 (47.2) |
| ≥1 comorbidity, n (%) | 517 (76.7) | 1224 (73.0) |
| Diabetes mellitus | 85 (12.6) | 207 (12.4) |
| COPD | 70 (10.4) | 129 (7.7) |
| Cardiac disorders | 61 (9.1) | 125 (7.5) |
| Neoplasms | 33 (4.9) | 41 (2.4) |
| Benign | 5 (0.7) | 10 (0.6) |
| Malignant | 17 (2.5) | 20 (1.0) |
| Unspecified † | 11 (1.6) | 13 (0.8) |
| Psychiatric disorders | 18 (2.7) | 41 (2.4) |
| Depressive disorders | 13 (1.9) | 37 (2.2) |
Data are mean (SD) unless indicated otherwise.
*Calculated.
†Neoplasms not classified as either benign or malignant. Information on malignancies at baseline was not routinely collected.
BMI, body mass index; CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; PtGA, Patient Global Assessment of disease activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.